🐎 Springer

Dear Author

Here are the proofs of your article.

- You can submit your corrections **online,** via **e-mail** or by **fax**.

- For **online** submission please insert your corrections in the online correction form. Always indicate the line number to which the correction refers.

- You can also insert your corrections in the proof PDF and **email** the annotated PDF.

- For **fax** submission, please ensure that your corrections are clearly legible. Use a fine black pen and write the correction in the margin, not too close to the edge of the page.

- Remember to note the **journal title**, **article number**, and **your name** when sending your response via e-mail or fax.

- **Check** the metadata sheet to make sure that the header information, especially author names and the corresponding affiliations are correctly shown.

- **Check** the questions that may have arisen during copy editing and insert your answers/corrections.

- **Check** that the text is complete and that all figures, tables and their legends are included. Also check the accuracy of special characters, equations, and electronic supplementary material if applicable. If necessary refer to the *Edited manuscript*.

- The publication of inaccurate data such as dosages and units can have serious consequences. Please take particular care that all such details are correct.

- Please **do not** make changes that involve only matters of style. We have generally introduced forms that follow the journal's style.

- Substantial changes in content, e.g., new results, corrected values, title and authorship are not allowed without the approval of the responsible editor. In such a case, please contact the Editorial Office and return his/her consent together with the proof.

- If we do not receive your corrections **within 48 hours**, we will send you a reminder.

- Your article will be published **Online First** approximately one week after receipt of your corrected proofs. This is the **official first publication** citable with the DOI. **Further changes are, therefore, not possible.**

- The **printed version** will follow in a forthcoming issue.

Please note

After online publication, subscribers (personal/institutional) to this journal will have access to the complete article via the DOI using the URL:

`http://dx.doi.org/10.1007/s10863-012-9428-1`

If you would like to know when your article has been published online, take advantage of our free alert service. For registration and further information, go to: http://www.springerlink.com.

Due to the electronic nature of the procedure, the manuscript and the original figures will only be returned to you on special request. When you return your corrections, please inform us, if you would like to have these documents returned.

Metadata of the article that will be visualized in OnlineFirst

1	Article Title	**Role of monocarboxylate transporters in human cancers: state of the art**		
2	Article Sub- Title			
3	Article Copyright - Year	**Springer Science+Business Media, LLC 2012** **(This will be the copyright line in the final PDF)**		
4	Journal Name	Journal of Bioenergetics and Biomembranes		
5		Family Name	**Baltazar**	
6		Particle		
7		Given Name	**Fátima**	
8		Suffix		
9		Organization	ICVS/3B's - PT Government Associate Laboratory	
10	Corresponding Author	Division		
11		Address	Braga/Guimarães , Portugal	
12		Organization	University of Minho	
13		Division	Life and Health Sciences Research Institute (ICVS), School of Health Sciences	
14		Address	Braga 4710-057, Portugal	
15		e-mail	fbaltazar@ecsaude.uminho.pt	
16		Family Name	**Pinheiro**	
17		Particle		
18		Given Name	**Céline**	
19		Suffix		
20		Organization	University of Minho	
21	Author	Division	Life and Health Sciences Research Institute (ICVS), School of Health Sciences	
22		Address	Braga 4710-057, Portugal	
23		Organization	ICVS/3B's - PT Government Associate Laboratory	
24		Division		
25		Address	Braga/Guimarães , Portugal	
26		e-mail		
27		Family Name	**Longatto-Filho**	
28	Author	Particle		
29		Given Name	**Adhemar**	

30		Suffix	
31		Organization	University of Minho
32		Division	Life and Health Sciences Research Institute (ICVS), School of Health Sciences
33		Address	Braga 4710-057, Portugal
34		Organization	ICVS/3B's - PT Government Associate Laboratory
35		Division	
36		Address	Braga/Guimarães , Portugal
37		Organization	University of São Paulo School of Medicine
38		Division	Laboratory of Medical Investigation (LIM) 14, Department of Pathology
39		Address	São Paulo , Brazil
40		e-mail	
41		Family Name	**Azevedo-Silva**
42		Particle	
43		Given Name	**João**
44		Suffix	
45	Author	Organization	University of Minho
46		Division	CBMA - Center of Molecular and Environmental Biology, Department of Biology
47		Address	Campus de Gualtar, Braga 4710-057, Portugal
48		e-mail	
49		Family Name	**Casal**
50		Particle	
51		Given Name	**Margarida**
52		Suffix	
53	Author	Organization	University of Minho
54		Division	CBMA - Center of Molecular and Environmental Biology, Department of Biology
55		Address	Campus de Gualtar, Braga 4710-057, Portugal
56		e-mail	
57		Family Name	**Schmitt**
58		Particle	
59		Given Name	**Fernando C.**
60	Author	Suffix	
61		Organization	University of Porto
62		Division	Medical Faculty
63		Address	Porto , Portugal

64		Organization	Institute of Molecular Pathology and Immunology of University of Porto
65		Division	IPATIMUP
66		Address	Porto , Portugal
67		e-mail	

71	Abstract	
72	Keywords separated by ' - '	
73	Foot note information	

1
3
2

MINI-REVIEW

4 # Role of monocarboxylate transporters in human cancers:
5 # state of the art

6 **Céline Pinheiro · Adhemar Longatto-Filho ·**
7 **João Azevedo-Silva · Margarida Casal ·**
8 **Fernando C. Schmitt · Fátima Baltazar**

9
10

11

Q1 12 **Abstract**

13 **Keywords**

14 ## Monocarboxylate transporter family

15 Monocarboxylic acids play a major role in cellular metabo-
16 lism, with lactate having a key function (Halestrap & Price
17 1999). Transport of monocarboxylates through the plasma
18 membrane was originally thought to be via non-ionic diffu-
19 sion of the free acid, however, subsequent demonstration
20 that lactate and pyruvate transport into human erythrocytes
21 could be strongly inhibited after treatment with some chem-
22 icals (Halestrap & Denton 1974), a specific monocarboxy-
23 late transport mechanism was recognized.

24 The monocarboxylate transporter (MCT) family is pres-
25 ently composed by 14 members, and is encoded by the
26 *SLC16* gene family (Halestrap & Meredith 2004), which is
27 conserved among species, including rat, mouse and chicken.

28 Functional and phylogenetic relationship of MCTs

29 According to the Transport Classification Database (www.
30 tcdb.org), MCTs are members of the Major Facilitator
31 Superfamily (Saier et al. 2009), belonging to the TC# 2.
32 A.1.13, the Monocarboxylate Porter (MCP) family. By shar-
33 ing a high level of conservative amino acid sequences, the
34 topological prediction of MCTs shows 12 transmembrane
35 helices (TMs), an intracellular N- and C-terminus and a
36 large cytosolic loop between TMs 6 and 7, with the most
37 conserved regions belonging to the TMs domains, and the
38 most variable ones matching the loops and the C-terminus
39 (Poole et al. 1996).

40 The 14 human MCT homologue members are assigned as
41 the solute carrier (SLC16A) gene series by the Human
42 Genome Organization (HUGO) Nomenclature Committee
43 Database (www.genenames.org). As shown in Fig. 1, the
44 phylogenetic analysis provides valuable information regard-
45 ing the functional clustering of the human MCT family. The
46 differences in amino acid sequence reflect an evolutionary
47 divergence associated with their functional role, since
48 MCT1-4, known to mediate the proton-linked transport of
49 metabolic monocarboxylic acids, appear associated in the
50 same cluster. This cluster is further sub-divided into two

C. Pinheiro · A. Longatto-Filho · F. Baltazar
Life and Health Sciences Research Institute (ICVS),
School of Health Sciences, University of Minho,
4710-057 Braga, Portugal

C. Pinheiro · A. Longatto-Filho · F. Baltazar (✉)
ICVS/3B's - PT Government Associate Laboratory,
Braga/Guimarães, Portugal
e-mail: fbaltazar@ecsaude.uminho.pt

A. Longatto-Filho
Laboratory of Medical Investigation (LIM) 14, Department of
Pathology, University of São Paulo School of Medicine,
São Paulo, Brazil

J. Azevedo-Silva · M. Casal
CBMA - Center of Molecular and Environmental Biology,
Department of Biology, University of Minho,
Campus de Gualtar,
Braga 4710-057, Portugal

F. C. Schmitt
Medical Faculty, University of Porto,
Porto, Portugal

F. C. Schmitt
IPATIMUP, Institute of Molecular Pathology and
Immunology of University of Porto,
Porto, Portugal

Fig. 1 Human MCT family members' phylogram, based on amino acid sequence. Boxes limited by dots represent three main clusters. In the doted-dashed box are the thyroid hormone (MCT8) and aromatic amino acids (MCT10) transporters. Solid grey box represent the proton-linked transported cluster (MCT1-4). The amino acid sequences were analyzed using CLUSTALW and tree plotting was performed using FigTree v1.3.1 (http://tree.bio.ed.ac.uk/). MCT1-14 UniProt accession numbers: P53985; O60669; O95907; O15427; O15374; O15375; O15403; P36021; Q7RTY1; Q8TF71; Q8NCK7; Q6ZSM3; Q7RTY0; Q7RTX9

Q3

shorter branches, the MCT1-2 and MCT3-4, which correlate with their range of substrate specificity and affinities found for the mammalian (human, mouse and rat) transporter isoforms (Table 1).

MCT1 has a broader distribution and transports a wider range of substrates when compared to other family members. Its kinetic parameters have been studied for the mouse isoform in tumor cells (Carpenter et al. 1996) and for the rat

Table 1 Km values (mM) of mammalian MCT isoforms for a range of monocarboxylates. (h) – human; (m) – mouse; (r) – rat; (*)- tumor cells

	MCT1 (Carpenter et al. 1996; Broer et al. 1998; Cuff et al. 2002; Kido et al. 2000; Poole et al. 1990)	MCT2 (Broer et al. 1999)	MCT4 (Dimmer et al. 2000; Manning Fox et al. 2000)
L-Lactate	$2.2^{(r)}$–$4.5^{(m*)}$	$0.7^{(r)}$	$28.0^{(h)}$–$34.0^{(r)}$
D-Lactate	$51.0^{(r)}$	–	$519.0^{(h)}$
Pyruvate	$0.6^{(r)}$–$1.0^{(r)}$	$0.08^{(r)}$	$153.0^{(h)}$
L-β-hydroxybutyrate	$8.1^{(r)}$–$11.4^{(m*)}$	n.d.	$824.0^{(h)}$
D-β-hydroxybutyrate	$8.1^{(r)}$–$10.1^{(m*)}$	$1.2^{(r)}$	$130.0^{(h)}$
Butyrate	$9.1^{(h*)}$	n.d.	n.d.
Acetoacetate	$5.5^{(r)}$	$0.8^{(r)}$	n.d.
Benzoate	$1.1^{(h)}$	n.d.	n.d.
Propionate	$1.5^{(r)}$	n.d.	n.d.
Acetate	$3.7^{(m*)}$	n.d.	n.d.

(*n.d.* not determined)

isoform expressed in *Xenopus laevis* oocytes (Broer et al. 1998). The main function of this transporter has been associated with the uptake or efflux of monocarboxylates through the plasma membrane, according to cell metabolic needs and behaving as a high affinity transporter for L-lactate, but not for D-lactate, as well as for pyruvate, acetate, propionate, D,L-β-hydroxybutyrate and acetoacetate (Halestrap & Meredith 2004). It has also been implicated in the transport of butyrate and propionate in human colonocytes (Cuff et al. 2002). Furthermore, its role in the uptake of benzoate in the human blood–brain barrier, as well as in vitro, using both immortalized and primary cultured brain capillary endothelial cells, has also been demonstrated (Kido et al. 2000).

The MCT2 rat ortholog was characterized by heterologous expression in *Xenopus laevis* oocytes (Broer et al. 1999), displaying a higher affinity for L-lactate, pyruvate, D-β-hydroxybutyrate and acetoacetate than MCT1. When expressed in the same tissue, MCT1 and MCT2 are located in distinct cells as they have been suggested to play different roles in metabolic shuttles (Garcia et al. 1995; Jackson et al. 1997).

MCT3 was first identified in chicken and displays a tissue-specific expression pattern, being only expressed in retinal pigment epithelium and choroid plexus epithelia, mediating the efflux of metabolic lactate in the retina (Philp et al. 1998; Bergersen et al. 1999). The heterologous expression of chick-MCT3 in yeast revealed a Km of 6 mM for L-lactate (Grollman et al. 2000).

The physiological role of the human MCT4 is mostly associated with the export of lactate in cells with high glycolytic rates related to hypoxic energy production (Dimmer et al. 2000). It was characterized by heterologous expression in *Xenopus laevis* oocytes (Manning Fox et al. 2000), exhibiting the highest Km values (Table 1) for most substrates and inhibitors when compared to MCT1 and MCT2.

Finally, MCT8 (rat isoform) and MCT10 (mouse isoform) mediate the transport of thyroid-hormones (Friesema et al. 2003) and aromatic amino acids (Kim et al. 2001) respectively, in a proton and sodium-independent manner. According to Fig. 1, their human orthologs share a closer phylogenetic relationship. For the remaining family members, few or no information is available about their properties and functional roles.

The role of MCTs in cell homeostasis is widely recognized and described in detail in some tissues. However, further work is needed in what concerns their role in tumor biology. Even so, if one looks at the microenvironmental scenario and molecular events occurring in carcinogenesis, it is possible to anticipate an important contribution of MCTs in the progression to malignancy.

Cancer cell metabolic adaptations

More than half a century ago, Otto Warburg demonstrated that cancer cells rapidly convert the majority of glucose into lactate, even in the presence of sufficient oxygen to support mitochondrial oxidative phosphorylation (Warburg 1956). This phenomenon is presently known as "aerobic glycolysis" or "Warburg effect". Although Warburg's hypothesis that impaired mitochondrial metabolism underlies the high rates of glycolysis has proven incorrect (Wang et al. 1976; Brand 1985; Moreno-Sanchez et al. 2007), the original observation of increased glycolysis in tumors has been confirmed repeatedly. In fact, this increased glucose uptake by cancer cells is the rationale behind the whole-body non-invasive ^{18}F-fluorodeoxyglucose positron emission tomography (FdG-PET) technique. This widespread clinical application is used for diagnosis, initial staging, restaging, prediction, monitoring of treatment response and surveillance in a variety of cancers (Jadvar et al. 2009).

Early carcinogenesis and development of the malignant phenotype occur in an avascular environment, and cancer cells become dependent on glucose and oxygen diffusion through blood vessels and basement membrane to fulfill their major metabolic demands (Gatenby & Gillies 2004; Gillies & Gatenby 2007). Hence, if early hyperplastic lesions develop further than a few cell layers beyond the basement membrane, regional development of hypoxia will occur, limiting cell growth. This intermittent hypoxia will promote selection for cells with anaerobic glycolysis constitutively up-regulated, allowing further cell growth (Gatenby & Gillies 2004; Gillies & Gatenby 2007; Smallbone et al. 2007). It is widely known that the major regulator of adaptation to hypoxic stress is the transcriptional factor HIF-1α, which has been widely associated with cancer progression (Semenza 1998a,b, 1999, 2000; 2001; Greijer et al. 2005). In fact, many enzymes from the glycolytic pathway like glucose transporter 1 (GLUT1) (Chen et al. 2001; Baumann et al. 2007), lactate dehydrogenase A (LDH-A) (Firth et al. 1995), among others (Greijer et al. 2005; Hu et al. 2003; Kim et al. 2006; Papandreou et al. 2006; Warnecke et al. 2004), are HIF-1α targets. Besides contributing to the constitutive glycolytic metabolism, HIF-1α also contributes to the acid-resistant phenotype, by up-regulating, at least, two important pH regulators, MCT4 (Ullah et al. 2006; de HF et al. 2009) and CAIX (Wykoff et al. 2000; Svastova et al. 2004; Chiche et al. 2009). In fact, MCT4 will not only be important for the acid-resistant phenotype, but also for the hyper-glycolytic phenotype, by exporting newly formed lactate, allowing continuous conversion of pyruvate to lactate and, therefore, continuous aerobic glycolysis.

The frequency and severity of tumor hypoxia and its association with malignant progression make the hypoxia-induced metabolic adaptations promising targets for cancer

therapy (Dang & Semenza 1999). Actually, the development of treatments that target tumor metabolism is receiving renewed attention, with several potential drugs targeting metabolic pathways currently in clinical trials (for review see (Porporato et al. 2011)). Importantly, MCT1 is included in this list of metabolic targets for cancer therapy.

The biological relevance of lactate transport in cancer

As already mentioned, the acid-resistant phenotype is an essential condition for cancer cell survival. Hence, different pH regulating systems are present in the plasma membrane of cancer cells, including MCTs, the Na^+/H^+ exchanger 1 (NHE1), carbonic anhydrase IX (CAIX) and anion exchanger 1 (AE1). Although MCTs are not the major H^+ transporters, they perform a double role in the adaptation to hypoxia: export of lactate, essential to the hyper-glycolytic phenotype, and pH regulation, important to the acid-resistant phenotype.

Besides its role as tumor acidifier, inducing mutagenesis/clastogenesis, cancer cell invasive behavior, radio- and chemoresistance (Gatenby & Gillies 2004), lactate has other properties which can contribute to the malignant behavior of cancer cells (Fig. 2). T cell activation is dependent on high rates of glycolysis and, therefore, dependent on a rapid efflux of lactate from T cells (Frauwirth & Thompson 2004). However, if the extracellular concentration of lactate is high, lactate efflux from T cells will be inhibited. This is the case of the tumor micromilieu and, as a consequence, T cell metabolism and function will be disturbed, decreasing the immune response against tumor cells (Fischer et al. 2007). Also, evidence shows that both lactate and pyruvate regulate hypoxia-inducible gene expression, independently from hypoxia, by stimulating the accumulation of HIF-1α (Lu et al. 2002). This indicates that, lactate, per se, stimulates the hyper-glycolytic phenotype, providing a positive feedback. Moreover, exogenous lactate was demonstrated to increase cellular motility (Walenta et al. 2002), vascular endothelial growth factor (VEGF), the major angiogenic factor (Spector et al. 2001; Kumar et al. 2007; Hunt et al. 2007), as well as hyaluronan and its receptor CD44, which are molecules involved in the process of cancer invasion and metastization (Stern et al. 2002; Rudrabhatla et al. 2006). Altogether, this evidence shows the various biological activities of lactate that can enhance the malignant phenotype of tumor cells, contributing to the association of high tumor lactate concentrations with incidence of metastases (Schwickert et al. 1995; Walenta et al. 1997; Walenta et al. 2000; Brizel et al. 2001), tumor recurrence, patient survival (Walenta et al. 2000; Brizel et al. 2001) and radioresistance (Quennet et al. 2006). As a result, MCTs, as the transporters responsible for lactate efflux from cancer cells, will be involved in the lactate-induced malignant behavior of cancer cells.

Besides being an end-product of different metabolic pathways, lactate may also be a substrate for oxidative phosphorylation and, as described in skeletal muscle and brain (Juel 1997; Pellerin et al. 1998), a cell-cell lactate shuttle has been proposed for cancer cells. Therefore, lactate has been recently described as the key metabolic intermediate in a metabolic symbiosis between glycolytic and oxidative cancer cells, in which the peripheral and oxygenated oxidative cells consume the lactate produced by the central and less oxygenated glycolytic cells (Fig. 2) (Sonveaux et al. 2008).

Although glucose is the major source of lactate in most solid tumors, it is important to note that other cancer pathways rather than glycolysis, like glutaminolysis and serinolysis (Mazurek et al. 2000, 2001a, b; DeBerardinis et al. 2007), can lead to lactate production. Nevertheless, lactate will always be an important metabolic end-product, either cancer cells use glycolysis or other energetic pathways for energy and biomass production.

MCT expression in human cancers

Although less explored than other proteins involved in the glycolytic phenotype or even than other pH regulators, reports on the role of MCTs in cancer are becoming more frequent with years (Table 2).

Colon

The first report on MCT expression in human tumor samples described a decrease of MCT1 expression (by Western blot) in the colonic transition from normality to malignancy (Ritzhaupt et al. 1998), which was further supported by a larger study analyzing MCT1, MCT2, and MCT4 expressions by Northern blot, Western blot and, immunohistochemistry only for MCT1, in healthy colon samples, adenomas and carcinomas. MCT1 protein decrease was confirmed, while MCT2 and MCT4 protein expression was not detected, despite mRNA expression of MCT4 (Lambert et al. 2002). However, more recent evidence showed a high expression of MCTs in colon adenocarcinoma (Pinheiro et al. 2010a), as well as significant increase of MCTs expression in cancer cells when comparing to normal colonic samples (Koukourakis et al. 2006; Pinheiro et al. 2008a). These contradictory results are probably due to antibody specificity, with special attention to the fact that the first immunohistochemical study failed to show MCT1 expression in the plasma membrane of cancer cells, which is essential for plasma membrane lactate efflux. In opposition, one of these recent studies showed a significant increase of MCT1 and MCT4 in the plasma membrane of colorectal cancer cells accompanied by a significant decrease in MCT2 at the plasma membrane. This finding is in accordance with the dependence of hyperglycolytic cancer cells in

Fig. 2 Overview on the metabolic pathways leading to lactate production (continuous lines) and transport across the plasma membrane, as well as strategies of lactate transport inhibition. Discontinuous arrows represent lactate uptake and flow inside oxidative cancer cells.

Abbreviations: CHC, α-cyano-4-hydroxycinnamic acid; LDH, lactate dehydrogenase; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1

262 exporting the accumulating lactate through MCT1 and MCT4,
263 but not MCT2. Additionally, MCT2 and MCT4 were strongly
264 expressed in the cytoplasm of cancer cells indicating a possible
265 role of these isoforms in the mitochondrial uptake of pyruvate
266 (Pinheiro et al. 2010a; Koukourakis et al. 2006; Pinheiro et al.
267 2008a). Importantly, analysis of MCT expression in regard to
268 the clinic-pathological parameters showed associations of
269 MCT1 plasma membrane expression with vascular invasion,
270 which could be explained by the role of extracellular lactate
271 and acidity on cancer cell invasion (Pinheiro et al. 2008a),
272 which will need further confirmation. Koukourakis and collab-
273 orators also found MCT1 expression in tumor-associated fibro-
274 blasts, favoring absorption of the accumulating lactate from the
275 extracellular matrix, to be used as energy source, as well as lack
276 of endothelial MCT1, to avoid lactate absorption and vascular
277 destruction by acidosis. Additionally, MCT2 was strongly
278 expressed in the cytoplasm of cancer cells and tumor-
279 associated fibroblasts, indicating a possible role of MCT2 in
280 the mitochondrial uptake of pyruvate. Finally, MCT4 was
281 weakly expressed in the tumor micromilieu, suggesting a

282 minimal role in the metabolic intratumoral communication
283 (Koukourakis et al. 2006).

284 Central nervous system

285 In neoplastic human tissues of the central nervous system,
286 the few existing studies point to a possible important role of
287 MCT expression, especially MCT1 (Froberg et al. 2001;
288 Mathupala et al. 2004; Fang et al. 2006; Li et al. 2009).
289 Strong expression of MCT1 was found in ependymomas,
290 hemangioblastomas and high grade glial neoplasms (ana-
291 plastic astrocytomas and glioblastoma multiforme (GBM)),
292 whereas low-grade glial neoplasms (oligodendrogliomas
293 and astrocytomas) were either negative or showed weak
294 MCT1 expression (Froberg et al. 2001). Additionally, West-
295 ern blot analysis in total protein extracts from normal brain
296 and primary brain tumors (GBMs) demonstrated that normal
297 brain predominantly expressed MCT3, whereas MCT1 and
298 MCT2 were the major isoforms present in GBM tumors.
299 MCT4 was not detected in any of the tumor tissues

t2.1 **Table 2** Overview on MCT1, MCT2, MCT4 and CD147 expression and prognosis in different tumor types

	Tumor site	MCT1 expression	MCT2 expression	MCT4 expression	CD147 expression*
t2.2					
t2.3	Colon	↓ from normality to malignancy (Ritzhaupt et al. 1998; Lambert et al. 2002)	Not detected in either normal or tumor tissues (Lambert et al. 2002)	Not detected in either normal or tumor tissues (Lambert et al. 2002)	(+) in tumor cells; no significant associations with MCTs (Pinheiro et al. 2010a)
t2.4		(+) in tumor cells but (−) normal epithelium (Koukourakis et al. 2006)	+ in tumor cells cytoplasm, but not in plasma membrane (Koukourakis et al. 2006)	Cytoplasm of cancer cells (Koukourakis et al. 2006)	
t2.5		↑ in tumor cells, compared to normal epithelium/associated with vascular invasion (Pinheiro et al. 2008a)	↑ in cytoplasm expression but ↓ in tumor cells plasma membrane compared to normal epithelium (Pinheiro et al. 2008a)	↑ in tumor cells, compared to normal epithelium (Pinheiro et al. 2008a)	
t2.6		(+) in tumor cells (Pinheiro et al. 2010a)	(+) in tumor cells (Pinheiro et al. 2010a)	(+) in tumor cells (Pinheiro et al. 2010a)	
t2.7	Central nervous system	Strongest in high grade glial neoplasms, compared to low grade glial neoplasms (Froberg et al. 2001)	↑ in glioblastoma, compared to normal tissue (Mathupala et al. 2004)	(-) in glioblastoma (Mathupala et al. 2004)	
t2.8		(+) in glioblastoma and (−) in normal tissue (Mathupala et al. 2004)			
t2.9		(+) in neuroblastoma/associated with age >1 year at diagnosis, stage 4 disease, unfavorable Shimada histopathology, DNA diploid index, *n-myc* amplification and high-risk clinical group (COG criteria) (Fang et al. 2006)			
t2.10	Breast	↓ due to gene hypermethylation (Asada et al. 2003)	(+) in tumor cells and normal epithelium cytoplasm, but not in plasma membrane (Pinheiro et al. 2010a)	Tendency to be ↑ in tumor cells, compared to normal epithelium (Pinheiro et al. 2010b)	(+) in tumor cells (Pinheiro et al. 2010a; Pinheiro et al. 2010b) and normal epithelium (Pinheiro et al. 2010b); significantly associated with MCT1 (Pinheiro et al. 2010b) and MCT4 (Pinheiro et al. 2010a, b)
t2.11		↑ in tumor cells, compared to normal epithelium/associated with basal-like subtype, high histological grade, estrogen and progesterone receptors, cytokeratins 5 and 14 and vimentin (alone or co-expressed with CD147) (Pinheiro et al. 2010b)		↑ in tumor cells, compared to normal epithelium (Pinheiro et al. 2010a)	
t2.12	Lung	Cytoplasmic accumulation in alveolar soft-part sarcoma (Ladanyi et al. 2002)	(+) in tumor cells but (−) normal epithelium (Koukourakis et al. 2007)	(+) in tumor cells but (−) normal epithelium (Koukourakis et al. 2007)	(+) in tumor cells; tendency to be associated with MCT1 and significantly associated with MCT4 (Pinheiro et al. 2010a)
t2.13		(+) in tumor cells but (−) normal epithelium (Koukourakis et al. 2007)	(+) in tumor cells and normal epithelium cytoplasm, but not in plasma membrane (Pinheiro et al. 2010a)	↓ in tumor cells, compared to normal epithelium (Pinheiro et al. 2010a)	
t2.14		(+) in tumor cells and normal epithelium (Pinheiro et al. 2010a)			
t2.15	Gynecologic tract	↑ from preinvasive to invasive cervical cancer/associated with metastases in AC (when co-expressed with CD147) (Pinheiro et al. 2008b)	No progressive change from preinvasive to invasive cervical cancer/↑ ASC (Pinheiro et al. 2008b)	↑ from preinvasive to invasive cervical cancer/↑ AC (Pinheiro et al. 2008b)	↑ from preinvasive to invasive cervical cancer; significant association with MCT1 and MCT4 but not MCT2 (Pinheiro et al. 2009a)

t2.17 **Table 2** (continued)

Tumor site	MCT1 expression	MCT2 expression	MCT4 expression	CD147 expression*
t2.16	(+) in ovarian tumor cells (Pinheiro et al. 2010a; Chen et al. 2010), but (−) in normal and benign epithelium (Chen et al. 2010)/associated with low grade, high FIGO stage, residual tumor, lack of tumor relapse and presence of ascites (Chen et al. 2010)	(+) in ovarian tumor cells cytoplasm, but not in plasma membrane (Pinheiro et al. 2010a)	(+) in ovarian tumor cells (Pinheiro et al. 2010a; Chen et al. 2010), but (−) in normal and benign epithelium (Chen et al. 2010)/associated with high grade, high FIGO stage, residual tumor, tumor relapse and presence of ascites (Chen et al. 2010)	(+) in ovarian tumor cells (Pinheiro et al. 2010a; Chen et al. 2010), but (−) in normal and benign epithelium (Chen et al. 2010); tendency to be associated with MCT1 (Pinheiro et al. 2010a), significantly associated with MCT1 and MCT4 (Chen et al. 2010)
t2.17 Prostate	(+) in tumor cells but (−) normal epithelium and PIN lesions/associated with high pretreatment PSA, high Gleason score, high pathological grade and nodal involvement (Hao et al. 2010)	↑ in tumor cells, compared to normal epithelium (Pertega-Gomes et al. 2011)	(+) in tumor cells but (−) normal epithelium and PIN lesions/associated with high pretreatment PSA, high Gleason score, high pathological grade and nodal involvement (Hao et al. 2010)	(+) in tumor cells but (−) normal epithelium and PIN lesions; co-localization with MCT1 and MCT4 (Hao et al. 2010)
t2.18	↓ in tumor cells, compared to normal epithelium/associated with high PSA, absence of perineural invasion and presence of biochemical recurrence (Pertega-Gomes et al. 2011)		↑ in tumor cells, compared to normal epithelium/high PSA levels, advanced tumor stage, higher Gleason score, presence of perineural invasion, and presence of biochemical recurrence (Pertega-Gomes et al. 2011)	(+) in tumor cells and normal epithelium; significantly associated with MCT1 and MCT4, but not MCT2 (Pertega-Gomes et al. 2011)
t2.19 Gastric	(+) with no change along progression/associated with advanced gastric cancer, Lauren's intestinal type, stage III+IV and lymph-node metastases when (co-expressed with CD147) (Pinheiro et al. 2009b)		↓ from normal tissue, to primary tumor, to lymph-node metastases/associated with early gastric cancer and Lauren's intestinal type (Pinheiro et al. 2009b)	(+) with no change along progression; significantly associated with MCT1 and MCT4 (Pinheiro et al. 2009b)

(Mathupala et al. 2004). A more recent study on the sympathetic nervous system tumor neuroblastoma, showed, by mRNA quantification, that MCT1 expression is also high and is associated with age >1 year at diagnosis, stage 4 disease, unfavorable Shimada histopathology, DNA diploid index, *n-myc* amplification and high-risk clinical group (Children's Oncology Group criteria) (Fang et al. 2006). Finally, expression analysis revealed that *SLC16A1* transcript, encoding for MCT1, was elevated in 90 % of the medulloblastomas analyzed (Li et al. 2009).

Breast

Evidence for MCT down-regulation was not only observed in colon carcinoma (Ritzhaupt et al. 1998; Lambert et al. 2002). In fact, silencing of *SLC16A1* by gene promoter hypermethylation was suggested in 4 of 20 breast cases (20 %), however, the resultant decrease of mRNA and protein were not demonstrated (Asada et al. 2003). In fact, results from our group showed a significant increase of MCT1 cytoplasmic and plasma membrane expression in breast carcinoma, when comparing to normal breast epithelium (Pinheiro et al. 2010a, b). MCT2 and MCT4 were also evaluated, however, while MCT2 was only present in the cytoplasm in a similar frequency in normal and tumor samples, MCT4 only showed a significant increase in tumor samples for cytoplasm expression (Pinheiro et al. 2010a), with no differences in plasma membrane expression (Pinheiro et al. 2010a, b). Importantly, MCT1, alone or in co-expression with CD147, was associated with basal-like subtype (a more aggressive breast cancer group) and other poor prognostic variables, including tumor high grade, pointing at an important role of MCT1/CD147 in breast carcinoma aggressiveness (Pinheiro et al. 2010b).

Lung

The literature is also controversial in lung cancer. In a first study by Koukourakis and collaborators, no expression of MCTs in normal lung was found, while expression of MCT1 was found in all tumors examined and both MCT2 and MCT4 were also expressed in cancer cells. This study also

analyzed the possible metabolic cooperation between lung cancer cells and tumor-associated stroma, however, tumor-associated stroma expressed MCTs weakly (Koukourakis et al. 2007). In opposition, a recent study by our group showed that normal lung presents a high frequency of MCT expression and, in fact, MCT4 is less expressed in tumor samples than in normal epithelium. However, as this last study was performed in a small number of cases, further work is needed to confirm these results (Pinheiro et al. 2010a). MCT1, in association with its chaperone CD147, was also described in the cytoplasm of alveolar soft part sarcoma (Ladanyi et al. 2002).

Gynecologic tract

MCT expression has also been described in some gynecological tumors like cervical and ovarian cancer (Pinheiro et al. 2010a, b; Chen et al. 2010). In cervical cancer, a significant increase in overall and plasma membrane expression of MCT1 and MCT4 was observed from pre-invasive to invasive squamous lesions and from normal glandular epithelium to adenocarcinomas. For MCT2, the significant alterations in the expression along the progression to the invasive phenotype did not follow a clear increase/decrease pattern. Also, MCT2 was more frequently observed in squamous cell carcinomas, while MCT4 was more frequently observed in adenocarcinomas. Importantly, high risk HPV-positive pre-invasive cases expressed more MCT1 and MCT4 than HPV negative pre-invasive cases, and also presented more MCT1 in plasma membrane (Pinheiro et al. 2008b). Additionally, CD147 was more frequently expressed in MCT1 and MCT4 positive cases and co-expression of MCT1 and CD147 was significantly associated with lymph-node metastasis in adenocarcinomas (Pinheiro et al. 2009a). In ovarian cancer, staining for MCT1 and MCT4 as well as their chaperone CD147 was not found in normal ovarian tissues and benign ovarian tissues, while around 80 % of epithelial ovarian primary and metastatic tumors showed expression of these proteins. MCT1 was significantly associated with low grade tumors, high FIGO stage, presence of residual tumor, lack of relapse and presence of ascites; MCT4 was significantly associated with high grade tumors, high FIGO stage, presence of residual tumor, relapse and presence of ascites. Importantly, MCT expression was associated with the expression of the multidrug resistance markers MDR1 and MRP2 (Chen et al. 2010). Our group also reported expression of MCT1, MCT2 and MCT4 in ovarian carcinoma, but with a lower frequency for MCT4 (around 45 %) and around 95 % for MCT2 (Pinheiro et al. 2010a).

Prostate

Association of MCTs with MDR1 was also described in prostate cancer (Hao et al. 2010). In this study, MCT1 and MCT4 were found to be expressed in around 90 % of prostate cancer cases, with 20 % of positive cases showing a weak immunostaining, while no expression was found in normal prostate tissues, prostate intraepithelial lesions or in non-tumor regions adjacent to primary prostate cancer tissues. Importantly MCT1 and MCT4 expressions were associated with high pretreatment PSA levels, high Gleason score, high pathological stage, and nodal involvement (Hao et al. 2010). In another study evaluating the expression of MCTs in prostate cancer (Pertega-Gomes et al. 2011), MCT1 was expressed in all normal samples and significantly less frequently expressed in tumor samples, being accompanied by its chaperone CD147. Conversely, MCT2 and MCT4 were significantly more frequently expressed in the cytoplasm of tumor cells when compared to normal tissue. All MCT isoforms and CD147 were expressed, at different frequencies, in PIN lesions. In accordance with some of the findings from the first study (Hao et al. 2010), MCT1 expression was associated with higher PSA levels, absence of perineural invasion, and presence of biochemical recurrence, while MCT4 expression was associated higher PSA levels, advanced tumor stage, higher Gleason score, presence of perineural invasion, and presence of biochemical recurrence (Pertega-Gomes et al. 2011). Further studies are warranted to better elucidate the expression pattern of MCTs in prostate tissues.

Stomach

In contrast to what was found in the previous types of tumors, neither MCT1 nor MCT4 were found to be up-regulated in gastric adenocarcinomas (Pinheiro et al. 2009b). Actually, MCT4 expression was more frequently observed in normal gastric mucosa than in gastric cancer cells and even less frequently observed in lymph-node metastasis, indicating a progressive loss of this MCT isoform with disease progression. Also, MCT4 expression was associated with Lauren's classification of intestinal-type carcinoma. MCT1 was similarly expressed in normal gastric mucosa, primary tumors and lymph-node metastasis, being present in the majority of samples (around 80 %). These findings may indicate that MCT1 has a major contribution in gastric homeostasis, which is maintained along carcinogenesis (Pinheiro et al. 2009b).

Overall, the data available in the literature support the hypothesis of a major role of MCTs in the emergence of the hyper-glycolytic and acid-resistant phenotypes, as adaptations to the hypoxic microenvironment. The up-regulation of MCTs in the plasma membrane of different type of tumors is an adaptive mechanism to allow continuous high glycolytic rates, by exporting the accumulating end-product, lactate, as well as to counteract acid-induced apoptosis or necrosis. However, this may not be the case for all tumor

types, hence, further studies characterizing MCT expression in other tumors are warranted.

MCTs as therapeutic targets in cancer

Considering the major role of MCTs in cancer metabolic adaptations, MCT inhibition will have a direct effect on cell pH regulation, therefore having an important effect on cancer cell viability. Also, MCTs have a crucial role as gatekeepers of the metabolic symbiosis between cancer cells (Sonveaux et al. 2008), so, targeting these transporters will "shut-down" the advantageous symbiosis, having an important impact on tumor homeostasis. Finally, taking into account the contribution of lactate to the malignant phenotype, together with the up-regulation of MCT in some tumors, MCT inhibition may be a useful therapeutic approach in cancer. This will then counteract the effects of lactate and, therefore, increase the immune response against tumor cells and decrease migration capacity of cells, among others.

In fact, it was demonstrated that in vitro MCT1 inhibition decreases intracellular pH (Sonveaux et al. 2008; Fang et al. 2006; Wahl et al. 2002), leads to cell death (Sonveaux et al. 2008; Mathupala et al. 2004; Fang et al. 2006; Wahl et al. 2002; Colen et al. 2006) and, importantly, enhances cancer cell radiosensitivity (Colen et al. 2006). Additionally, silencing of MCT4 results in decreased cancer cell migration (Gallagher et al. 2007), by mechanisms that also involve interaction of MCT4 with β_1-integrin (Gallagher et al. 2009). In opposition, another study showed that silencing of MCT1 or MCT4 inhibited cancer cell invasion, but did not influence cell migration (Izumi et al. 2011). Importantly, promising results using in vivo models have also been reported, where administration of α-cyano-4-hydroxycinnamic acid (CHC), a classical non-specific inhibitor of MCT1 (Fig. 1), retarded tumor growth, rendered tumor cells sensitive to radiation (Sonveaux et al. 2008), induced tumor necrosis and decreased tumor invasion (Colen et al. 2011). The importance of MCTs for in vivo tumor growth was confirmed by a more specific approach, where combined silencing of MCT1 and MCT4 or silencing of CD147 significantly reduced glycolytic flux and tumor growth (Le et al. 2011). There are also other MCT inhibitors described (Fig. 1) (Le et al. 2011; Ovens et al. 2010; Wang & Morris 2007; Belt et al. 1979; Kobayashi et al. 2006; Ben-Horin et al. 1995; Ben-Yoseph et al. 1998), which are either non-isoform specific (AR-C155858 targets both MCT1 and MCT2 (Ovens et al. 2010)) or target other molecules besides MCTs (e.g., lonidamine primary target is hexokinase II (Floridi et al. 1981)). However, these compounds have been little explored as lactate transport inhibitors in the cancer context (Le et al. 2011; Wang & Morris 2007; Belt et al. 1979; Ben-Yoseph et al. 1998).

MCT regulation by chaperones

As previously mentioned, functional expression of MCTs is regulated by accessory proteins, such as CD147, that are involved in trafficking and anchoring of plasma membrane proteins.

Regulation of MCT1 and MCT4, but not MCT2, by CD147, was supported by evidence on human tissues (Pinheiro et al. 2009a, b,2010a, b), complementing the in vitro and some in vivo studies previously described (Gallagher et al. 2007; Kirk et al. 2000; Makuc et al. 2004; Philp et al. 2003; Deora et al. 2005; Wilson et al. 2005). Indeed, the prognostic value of CD147 appears to be associated with its co-expression with MCT1, as observed in breast and gastric carcinomas (Pinheiro et al. 2009b, 2010b). Therefore, targeting CD147, which will also impair MCT activity, appears to be a rational therapeutic approach against human cancer, as already described both in vitro and in vivo (Schneiderhan et al. 2009; Su et al. 2009; Baba et al. 2008). Besides the role of CD147 as chaperone for MCT1 and MCT4 plasma membrane trafficking and activity, these MCT isoforms also have been implicated in CD147 proper membrane expression (Gallagher et al. 2007; Deora et al. 2005). Thus, the contribution of MCTs to the malignant phenotype is not limited to their own function as lactate transporters and pH regulators, but may also be further enhanced by their role in regulating CD147 expression. If so, MCTs may also have indirect roles in tumor growth and angiogenesis, as well as cancer cell migration and invasion (Nabeshima et al. 2006; Yan et al. 2005; Iacono et al. 2007; Slomiany et al. 2009).

In vitro studies show that CD44 may also function as a chaperone for MCT expression (Slomiany et al. 2009). Additionally, parallel analysis of CD44 and MCTs expressions in human cancer samples, show that CD44 is associated with MCT1 in lung cancer (Pinheiro et al. 2010a) and both MCT1 and MCT4 in prostate cancer (Hao et al. 2010). As a result, MCT expression may also have a role in cell growth control, adhesion, migration, invasion, and chemoresistance (Marhaba & Zoller 2004; Toole & Slomiany 2008a, b), through interaction with CD44.

Importantly, there is a relevant number of cases with MCT plasma membrane expression lacking ~~both~~ CD147 or CD44 in the plasma membrane ~~co-expression~~, suggesting that a not yet identified chaperone may be involved in MCT trafficking to the plasma membrane.

Conclusion

Carcinogenesis has been viewed as a progressive process described as "somatic evolution" as it requires a sequence of genetic changes; however, recent models of carcinogenesis

integrate the neo-Darwinian evolution, stating that phenotypic properties are retained or lost based on their contribution to fitness for survival, with cell-environment interactions. This new concept of carcinogenesis was applied to explain the Warburg phenomenon, i.e., the preference for the glycolytic phenotype, even in the presence of oxygen. Thus, as cancer progression proceeds, mutations in tumor cells increase and traits that are found in invasive cancers, like the hyper-glycolytic and acid-resistant phenotypes, arise as adaptive mechanisms to environmental proliferative constraints, such as hypoxia.

Many players have been associated with these cellular adaptations; however, although an important role of lactate transporters could be anticipated in the context of the Warburg effect, the underlying role of MCTs in solid tumors are far from being understood. Thus, additional studies characterizing MCT expression in tumor types not yet analyzed, confirmation of the results already published as well as additional functional studies are needed to reinforce the contribution of MCTs for cancer maintenance and aggressiveness.

References

Asada K, Miyamoto K, Fukutomi T, Tsuda H, Yagi Y, Wakazono K, Oishi S, Fukui H, Sugimura T, Ushijima T (2003) Reduced expression of GNA11 and silencing of MCT1 in human breast cancers. Oncology 64:380–8

Baba M, Inoue M, Itoh K, Nishizawa Y (2008) Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun 374:111–6

Baumann MU, Zamudio S, Illsley NP (2007) Hypoxic upregulation of glucose transporters in BeWo choriocarcinoma cells is mediated by hypoxia-inducible factor-1. Am J Physiol Cell Physiol 293:C477–C485

Belt JA, Thomas JA, Buchsbaum RN, Racker E (1979) Inhibition of lactate transport and glycolysis in Ehrlich ascites tumor cells by bioflavonoids. Biochemistry 18:3506–11

Ben-Horin H, Tassini M, Vivi A, Navon G, Kaplan O (1995) Mechanism of action of the antineoplastic drug lonidamine: 31P and 13C nuclear magnetic resonance studies. Cancer Res 55:2814–21

Ben-Yoseph O, Lyons JC, Song CW, Ross BD (1998) Mechanism of action of lonidamine in the 9 L brain tumor model involves inhibition of lactate efflux and intracellular acidification. J Neurooncol 36:149–57

Bergersen L, Johannsson E, Veruki ML, Nagelhus EA, Halestrap A, Sejersted OM, Ottersen OP (1999) Cellular and subcellular expression of monocarboxylate transporters in the pigment epithelium and retina of the rat. Neuroscience 90:319–31

Brand K (1985) Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. Biochem J 228:353–61

Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W (2001) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51:349–53

Broer S, Schneider HP, Broer A, Rahman B, Hamprecht B, Deitmer JW (1998) Characterization of the monocarboxylate transporter 1 expressed in Xenopus laevis oocytes by changes in cytosolic pH. Biochem J 333(Pt 1):167–74

Broer S, Broer A, Schneider HP, Stegen C, Halestrap AP, Deitmer JW (1999) Characterization of the high-affinity monocarboxylate transporter MCT2 in Xenopus laevis oocytes. Biochem J 341(Pt 3):529–35

Carpenter L, Poole RC, Halestrap AP (1996) Cloning and sequencing of the monocarboxylate transporter from mouse Ehrlich Lettre tumour cell confirms its identity as MCT1 and demonstrates that glycosylation is not required for MCT1 function. Biochim Biophys Acta 1279:157–63

Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276:9519–25

Chen H, Wang L, Beretov J, Hao J, Xiao W, Li Y (2010) Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression. Clin Exp Metastasis 27:557–69

Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouyssegur J (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69:358–68

Colen CB, Seraji-Bozorgzad N, Marples B, Galloway MP, Sloan AE, Mathupala SP (2006) Metabolic remodeling of malignant gliomas for enhanced sensitization during radiotherapy: an in vitro study. Neurosurgery 59:1313–23

Colen CB, Shen Y, Ghoddoussi F, Yu P, Francis TB, Koch BJ, Monterey MD, Galloway MP, Sloan AE, Mathupala SP (2011) Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia 13:620–32

Cuff MA, Lambert DW, Shirazi-Beechey SP (2002) Substrate-induced regulation of the human colonic monocarboxylate transporter, MCT1. J Physiol 539:361–71

Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24:68–72

Perez de HF, Wood IS, Trayhurn P (2009) Hypoxia stimulates lactate release and modulates monocarboxylate transporter (MCT1, MCT2, and MCT4) expression in human adipocytes. Pflugers Arch

DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 104:19345–50

Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E (2005) Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci U S A 102:16245–50

Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S (2000) The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 350(Pt 1):219–27

Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 70:2108–15

Firth JD, Ebert BL, Ratcliffe PJ (1995) Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270:21021–7

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109:3812–9

660 Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De MC
661 (1981) Lonidamine, a selective inhibitor of aerobic glycolysis of
662 murine tumor cells. J Natl Cancer Inst 66:497–9
663 Frauwirth KA, Thompson CB (2004) Regulation of T lymphocyte
664 metabolism. J Immunol 172:4661–5
665 Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP,
666 Visser TJ (2003) Identification of monocarboxylate transporter
667 8 as a specific thyroid hormone transporter. J Biol Chem
668 278:40128–35
669 Froberg MK, Gerhart DZ, Enerson BE, Manivel C, Guzman-Paz M,
670 Seacotte N, Drewes LR (2001) Expression of monocarboxylate
671 transporter MCT1 in normal and neoplastic human CNS tissues.
672 Neuroreport 12:761–5
673 Gallagher SM, Castorino JJ, Wang D, Philp NJ (2007) Monocarbox-
674 ylate transporter 4 regulates maturation and trafficking of CD147
675 to the plasma membrane in the metastatic breast cancer cell line
676 MDA-MB-231. Cancer Res 67:4182–9
677 Gallagher SM, Castorino JJ, Philp NJ (2009) Interaction of monocar-
678 boxylate transporter 4 with {beta}1-integrin and its role in cell
679 migration. Am J Physiol Cell Physiol 296:C414–C421
680 Garcia CK, Brown MS, Pathak RK, Goldstein JL (1995) cDNA clon-
681 ing of MCT2, a second monocarboxylate transporter expressed in
682 different cells than MCT1. J Biol Chem 270:1843–9
683 Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic
684 glycolysis? Nat Rev Cancer 4:891–9
685 Gillies RJ, Gatenby RA (2007) Adaptive landscapes and emergent
686 phenotypes: why do cancers have high glycolysis? J Bioenerg
687 Biomembr 39:251–7
688 Greijer AE, van der GP, Kemming D, Shvarts A, Semenza GL, Meijer
689 GA, van de Wiel MA, Belien JA, van Diest PJ, van der WE
690 (2005) Up-regulation of gene expression by hypoxia is mediated
691 predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol
692 206:291–304
693 Grollman EF, Philp NJ, McPhie P, Ward RD, Sauer B (2000) Deter-
694 mination of transport kinetics of chick MCT3 monocarboxylate
695 transporter from retinal pigment epithelium by expression in
696 genetically modified yeast. Biochemistry 39:9351–7
697 Halestrap AP, Denton RM (1974) Specific inhibition of pyruvate
698 transport in rat liver mitochondria and human erythrocytes by
699 alpha-cyano-4-hydroxycinnamate. Biochem J 138:313–6
700 Halestrap AP, Meredith D (2004) The SLC16 gene family-from
701 monocarboxylate transporters (MCTs) to aromatic amino acid
702 transporters and beyond. Pflugers Arch 447:619–28
703 Halestrap AP, Price NT (1999) The proton-linked monocarboxylate
704 transporter (MCT) family: structure, function and regulation.
705 Biochem J 343(Pt 2):281–99
706 Hao J, Chen H, Madigan MC, Cozzi PJ, Beretov J, Xiao W, Delprado
707 WJ, Russell PJ, Li Y (2010) Co-expression of CD147 (EMM-
708 PRIN), CD44v3-10, MDR1 and monocarboxylate transporters is
709 associated with prostate cancer drug resistance and progression.
710 Br J Cancer 103:1008–18
711 Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC (2003) Differen-
712 tial roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and
713 HIF-2alpha in hypoxic gene regulation. Mol Cell Biol
714 23:9361–74
715 Hunt TK, Aslam RS, Beckert S, Wagner S, Ghani QP, Hussain MZ,
716 Roy S, Sen CK (2007) Aerobically derived lactate stimulates
717 revascularization and tissue repair via redox mechanisms. Anti-
718 oxid Redox Signal 9:1115–24
719 Iacono KT, Brown AL, Greene MI, Saouaf SJ (2007) CD147 immu-
720 noglobulin superfamily receptor function and role in pathology.
721 Exp Mol Pathol 83:283–95
722 Izumi H, Takahashi M, Uramoto H, Nakayama Y, Oyama T, Wang KY,
723 Sasaguri Y, Nishizawa S, Kohno K (2011) Monocarboxylate
724 transporters 1 and 4 are involved in the invasion activity of human
725 lung cancer cells. Cancer Sci 102:1007–13

726 Jackson VN, Price NT, Carpenter L, Halestrap AP (1997) Cloning of
727 the monocarboxylate transporter isoform MCT2 from rat testis
728 provides evidence that expression in tissues is species-specific
729 and may involve post-transcriptional regulation. Biochem J 324
730 (Pt 2):447–53
731 Jadvar H, Alavi A, Gambhir SS (2009) 18 F-FDG uptake in lung,
732 breast, and colon cancers: molecular biology correlates and
733 disease characterization. J Nucl Med 50:1820–7
734 Juel C (1997) Lactate-proton cotransport in skeletal muscle. Physiol
735 Rev 77:321–58
736 Kido Y, Tamai I, Okamoto M, Suzuki F, Tsuji A (2000) Functional
737 clarification of MCT1-mediated transport of monocarboxylic
738 acids at the blood-brain barrier using in vitro cultured cells and
739 in vivo BUI studies. Pharm Res 17:55–62
740 Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H
741 (2001) Expression cloning of a Na+-independent aromatic amino
742 acid transporter with structural similarity to H+/monocarboxylate
743 transporters. J Biol Chem 276:17221–8
744 Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-
745 mediated expression of pyruvate dehydrogenase kinase: a meta-
746 bolic switch required for cellular adaptation to hypoxia. Cell
747 Metab 3:177–85
748 Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP
749 (2000) CD147 is tightly associated with lactate transporters
750 MCT1 and MCT4 and facilitates their cell surface expression.
751 EMBO J 19:3896–904
752 Kobayashi M, Otsuka Y, Itagaki S, Hirano T, Iseki K (2006) Inhibitory
753 effects of statins on human monocarboxylate transporter 4. Int J
754 Pharm 317:19–25
755 Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E (2006)
756 Comparison of metabolic pathways between cancer cells and
757 stromal cells in colorectal carcinomas: a metabolic survival role
758 for tumor-associated stroma. Cancer Res 66:632–7
759 Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E (2007)
760 Lung cancer: a comparative study of metabolism related protein
761 expression in cancer cells and tumor associated stroma. Cancer
762 Biol Ther 6:1476–9
763 Kumar VB, Viji RI, Kiran MS, Sudhakaran PR (2007) Endothelial cell
764 response to lactate: implication of PAR modification of VEGF. J
765 Cell Physiol 211:477–85
766 Ladanyi M, Antonescu CR, Drobnjak M, Baren A, Lui MY, Golde
767 DW, Cordon-Cardo C (2002) The precrystalline cytoplasmic
768 granules of alveolar soft part sarcoma contain monocarboxylate
769 transporter 1 and CD147. Am J Pathol 160:1215–21
770 Lambert DW, Wood IS, Ellis A, Shirazi-Beechey SP (2002) Molecular
771 changes in the expression of human colonic nutrient transporters
772 during the transition from normality to malignancy. Br J Cancer
773 86:1262–9
774 Le FR, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, Critchlow
775 SE, Roux D, Simon MP, Pouyssegur J (2011) CD147 subunit of
776 lactate/H+symporters MCT1 and hypoxia-inducible MCT4 is
777 critical for energetics and growth of glycolytic tumors. Proc Natl
778 Acad Sci U S A 108:16663–8
779 Li KK, Pang JC, Ching AK, Wong CK, Kong X, Wang Y, Zhou L,
780 Chen Z, Ng HK (2009) miR-124 is frequently down-regulated in
781 medulloblastoma and is a negative regulator of SLC16A1. Hum
782 Pathol 40:1234–43
783 Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activa-
784 tion by aerobic glycolysis implicates the Warburg effect in carci-
785 nogenesis. J Biol Chem 277:23111–5
786 Makuc J, Cappellaro C, Boles E (2004) Co-expression of a mammalian
787 accessory trafficking protein enables functional expression of the
788 rat MCT1 monocarboxylate transporter in Saccharomyces cerevi-
789 siae. FEMS Yeast Res 4:795–801
790 Manning Fox JE, Meredith D, Halestrap AP (2000) Characterisation of
791 human monocarboxylate transporter 4 substantiates its role in

lactic acid efflux from skeletal muscle. J Physiol 529(Pt 2):285–93

Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35:211–31

Mathupala SP, Parajuli P, Sloan AE (2004) Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery 55:1410–9

Mazurek S, Grimm H, Oehmke M, Weisse G, Teigelkamp S, Eigenbrodt E (2000) Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res 20:5151–4

Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E (2001a) Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 356:247–56

Mazurek S, Zwerschke W, Jansen-Durr P, Eigenbrodt E (2001b) Metabolic cooperation between different oncogenes during cell transformation: interaction between activated ras and HPV-16 E7. Oncogene 20:6891–8

Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E (2007) Energy metabolism in tumor cells. FEBS J 274:1393–418

Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M (2006) Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56:359–67

Ovens MJ, Davies AJ, Wilson MC, Murray CM, Halestrap AP (2010) AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J 425:523–30

Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187–97

Pellerin L, Pellegri G, Bittar PG, Charnay Y, Bouras C, Martin JL, Stella N, Magistretti PJ (1998) Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci 20:291–9

Pertega-Gomes N, Vizcaino JR, Miranda-Goncalves V, Pinheiro C, Silva J, Pereira H, Monteiro P, Henrique RM, Reis RM, Lopes C, Baltazar F (2011) Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer 11:312

Philp NJ, Yoon H, Grollman EF (1998) Monocarboxylate transporter MCT1 is located in the apical membrane and MCT3 in the basal membrane of rat RPE. Am J Physiol 274:R1824–R1828

Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ (2003) Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/basigin-null mouse. Invest Ophthalmol Vis Sci 44:1305–11

Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F (2008a) Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch 452:139–46

Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, Jube LF, Queiroz GS, Schmitt F, Baltazar F (2008b) Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol 27:568–74

Pinheiro C, Longatto A, Pereira SMM, Etlinger D, Moreira MAR, Jube LF, Queiroz GS, Schmitt F, Baltazar F (2009a) Monocarboxylate transporters 1 and 4 are associated with CD147 in cervical carcinoma. Disease Markers 26:97–103

Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, Zilberstein B, Cecconello I, Alves VA, Schmitt F, Baltazar F (2009b) The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Eur J Cancer 45:2418–24

Pinheiro C, Reis RM, Ricardo S, Longatto-Filho A, Schmitt F, Baltazar F (2010a) Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol 2010:427694

Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F (2010b) Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. Histopathology 56:860–7

Poole RC, Cranmer SL, Halestrap AP, Levi AJ (1990) Substrate and inhibitor specificity of monocarboxylate transport into heart cells and erythrocytes. Further evidence for the existence of two distinct carriers. Biochem J 269:827–9

Poole RC, Sansom CE, Halestrap AP (1996) Studies of the membrane topology of the rat erythrocyte H+/lactate cotransporter (MCT1). Biochem J 320(Pt 3):817–24

Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P (2011) Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol 2:49

Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, Mueller-Klieser W (2006) Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 81:130–5

Ritzhaupt A, Wood IS, Ellis A, Hosie KB, Shirazi-Beechey SP (1998) Identification of a monocarboxylate transporter isoform type 1 (MCT1) on the luminal membrane of human and pig colon. Biochem Soc Trans 26:S120

Rudrabhatla SR, Mahaffey CL, Mummert ME (2006) Tumor microenvironment modulates hyaluronan expression: the lactate effect. J Invest Dermatol 126:1378–87

Saier MH Jr, Yen MR, Noto K, Tamang DG, Elkan C (2009) The Transporter Classification Database: recent advances. Nucleic Acids Res 37:D274–D278

Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, Buchholz M, Gress TM, Adler G, Seufferlein T, Oswald F (2009) CD147 Silencing Inhibits Lactate Transport and Reduces Malignant Potential of pancreatic cancer cells in in-vivo and in-vitro Models. Gut 58:1391–8

Schwickert G, Walenta S, Sundfor K, Rofstad EK, Mueller-Klieser W (1995) Correlation of high lactate levels in human cervical cancer with incidence of metastasis. Cancer Res 55:4757–9

Semenza GL (1998a) Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 131:207–14

Semenza GL (1998b) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8:588–94

Semenza GL (1999) Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:551–78

Semenza GL (2000) Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35:71–103

Semenza GL (2001) Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatr Res 49:614–7

Slomiany MG, Grass GD, Robertson AD, Yang XY, Maria BL, Beeson C, Toole BP (2009) Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 69:1293–301

Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Gavaghan DJ (2007) Metabolic changes during carcinogenesis: potential impact on invasiveness. J Theor Biol 244:703–13

Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930–42

Spector JA, Mehrara BJ, Greenwald JA, Saadeh PB, Steinbrech DS, Bouletreau PJ, Smith LP, Longaker MT (2001) Osteoblast expression of vascular endothelial growth factor is modulated by the extracellular microenvironment. Am J Physiol Cell Physiol 280: C72–C80

Stern R, Shuster S, Neudecker BA, Formby B (2002) Lactate stimulates fibroblast expression of hyaluronan and CD44: the Warburg effect revisited. Exp Cell Res 276:24–31

Su J, Chen X, Kanekura T (2009) A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 273:140–7

Svastova E, Hulikova A, Rafajova M, Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, Pastorekova S (2004) Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577:439–45

Toole BP, Slomiany MG (2008a) Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 18:244–50

Toole BP, Slomiany MG (2008b) Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat 11:110–21

Ullah MS, Davies AJ, Halestrap AP (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281:9030–7

Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS (2002) Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 1:617–28

Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, Mueller-Klieser W (1997) Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 150:409–15

Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W (2000) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60:916–21

Walenta S, Schroeder T, Mueller-Klieser W (2002) Metabolic mapping with bioluminescence: basic and clinical relevance. Biomol Eng 18:249–62

Wang Q, Morris ME (2007) Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos 35:201–8

Wang T, Marquardt C, Foker J (1976) Aerobic glycolysis during lymphocyte proliferation. Nature 261:702–5

Warburg O (1956) On the origin of cancer cells. Science 123:309–14

Warnecke C, Zaborowska Z, Kurreck J, Erdmann VA, Frei U, Wiesener M, Eckardt KU (2004) Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J 18:1462–4

Wilson MC, Meredith D, Fox JE, Manoharan C, Davies AJ, Halestrap AP (2005) Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70). J Biol Chem 280:27213–21

Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–83

Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93:199–204

AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES.

Q1. Keywords are desired. Please provide. Otherwise, please confirm if unnecessary.
Q2. References 95 and 99 based on original manuscript we received were identical. Hence, the latter was deleted and reference list and citations were adjusted. Please check if appropriate.
Q3. Figure 1 Contains blurry text. Please provide replacement otherwise, please advise if we can proceed with the figure/s as is.
Q4. Please check captured affiliation if appropriate.